PMS33 PARTICIPATION, SATISFACTION AND KNOWLEDGE LEVEL AMONG PSORIATIC ARTHRITIS AND CUTANEOUS PSORIASIS PATIENTS  by Tabolli, S et al.
A128 Abstracts
WTP threshold, certolizumab may be the most cost-effective agent for the treatment 
of rheumatoid arthritis compared to all other TNF-alpha inhibitors.
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CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT 
(ORENCIATM) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY 
ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE 
RESPONSE TO METHOTREXATE
Zou D1, Desjardins O2, Tsao N1, Goeree R3
1Oxford Outcomes, Vancouver, BC, Canada, 2Bristol-Myers Squibb, Montreal, QC, Canada, 
3Oxford Outcomes, Toronto, ON, Canada
BACKGROUND: Biological therapies including inﬂiximab, etanercept, adalimumab 
and abatacept are options for rheumatoid arthritis (RA) patients who had an inade-
quate response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs), such as 
methotrexate (MTX). OBJECTIVES: To determine the cost-effectiveness of abatacept 
compared to other biologics in the treatment of moderate-to-severe active RA in 
patients with inadequate response to MTX in Canada. METHODS: An existing US-
based cost-effectiveness model was adapted to the Canadian setting. The techniques 
of dynamic simulation were employed to estimate the impact of abatacept and other 
biologics on functional disability (expressed in patients’ Health Assessment Question-
naire (HAQ) scores) and clinical and economic outcomes. The model focuses on a 
hypothetical cohort of patients, simulating their disability quarterly over 1, 5, 10 years 
and lifetime. First-order simulation was conducted to gauge the inﬂuence of individual 
input parameters. Second-order Monte Carlo simulation was performed to examine 
the overall effect of uncertainty in the model. Efﬁcacy data were based on a separate 
meta-analysis. The perspective adopted was that of a provincial ministry of health. 
Utility data were obtained from a study that mapped Health Utility Index values on 
a Canadian RA population. Costs (2009 CAD) and outcomes were discounted at 5% 
annually. RESULTS: Abatacept has a cost-effectiveness ratio of approximately 
$93,000 per QALY gained vs. MTX, comparable with those of etanercept ($96,000) 
and adalimumab ($112,000) and much lower than that of inﬂiximab ($171,000). At 
willingness-to-pay between $80,000 and $97,000, abatacept is the most cost-effective 
option. Results were most sensitive to the assumption of the threshold for clinically 
meaningful HAQ improvement at 6-month and applied time horizon. CONCLU-
SIONS: Determination of an appropriate biological therapy in RA depends on multiple 
factors including economic value. Abatacept offers a valuable therapeutic option for 
the treatment of moderate-to-severe active RA in patients with inadequate response 
to one or more DMARD therapies.
PMS30
ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN 
PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC  
PAIN
Wang J1, Liu X2, Mullins CD3
1The University of Tennessee, Memphis, TN, USA, 2Eli Lilly and Company, Indianapolis, IN, 
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OBJECTIVES: Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has 
been approved for the treatment of both major depressive disorder (MDD) and certain 
chronic pain-related diseases (CPD). This study examined the association between 
adherence to duloxetine and hospital utilization among MDD patients with CPD. 
METHODS: This is a retrospective cohort study analyzing data from the MarketScan 
commercial databases. Patients were included in the analyses if they used duloxetine 
during the index period of July 1, 2006-June 30, 2007 and had no record of duloxetine 
use during a 3-month washout period. Inclusion criteria required MDD diagnosis and 
at least one CPD of interest (ﬁbromyalgia, diabetes with neurological manifestations, 
low back pain, headache, and osteoarthritis). Patients were followed up 12 months 
after index date. Adherence was deﬁned as medication possession ratio (MPR) of 80% 
or higher. Hospital utilization included emergency room visits and hospitalizations. 
Psychiatric hospitalizations were based on principal diagnosis codes for admissions. 
Logistic regression and negative binomial regression models were used to adjust for 
patient characteristics. RESULTS: Compared to those with MPR < 80% (n = 2,988), 
patients adherent to duloxetine (n = 2,589) had fewer emergency room visits (1.51 vs. 
2.07; p < 0.0001), lower likelihood of emergency room visit (36.85% vs. 41.57%; p 
= 0.0003), fewer all-cause hospitalizations (0.34 vs. 0.46; p < 0.0001), fewer psychi-
atric hospitalizations (0.10 vs. 0.15; p < 0.0001), fewer all-cause hospitalization days 
(1.46 vs. 2.43; p < 0.0001), fewer psychiatric hospitalization days (0.53 vs. 1.04; p = 
0.0001), lower likelihood of hospitalization for any cause (20.97% vs. 25.07%; 
p = 0.0003) and lower likelihood of psychiatric hospitalization (6.80% vs. 8.97%; 
p = 0.0028). These differences were essentially the same after adjusting for patient 
characteristics. CONCLUSIONS: Adherence to duloxetine was associated with lower 
hospital utilization among MDD patients with CPD, suggesting the importance of 
improving patient adherence to duloxetine. Future studies should examine whether 
the lower hospital utilization associated with duloxetine adherence translates to lower 
costs.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies
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AN EVENT-LEVEL ANALYSIS OF PRESCRIPTION REFILL INTERVALS 
FOR ADALIMUMAB AND ETANERCEPT IN THE TREATMENT OF 
RHEUMATOID ARTHRITIS
Rizzo J1, Gunnarsson C2, Fang H3, Carter C4, Bolge S4, McKenzie RS4
1Stony Brook University, Stony Brook, NY, USA, 2S2 Statistical Solutions Inc, Cincinnati, OH, 
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OBJECTIVES: To assess differences in rates of shorter, longer, and on-time prescrip-
tion reﬁll intervals for adalimumab and etanercept in rheumatoid arthritis (RA) and 
to identify factors associated with rates of longer prescription reﬁll intervals. 
METHODS: An event-level analysis was conducted using medical/pharmacy claims 
from a database of 98 managed care plans. Inclusion criteria included index tumor 
necrosis factor inhibitor (anti-TNF) started January 2004-December 2007, patient age 
≥18, 2 RA diagnosis codes (ICD-9 code 714.xx), and 365 days of index anti-TNF 
treatment. Patients with selected other inﬂammatory conditions or evidence of anti-
TNFs during 6 months prior to index date or abatacept or rituximab while on index 
anti-TNF were excluded. Prescription reﬁll intervals were assessed by comparing the 
observed time between dates of prescription claims with recommended dosing fre-
quency in prescribing information (i.e., adalimumab = 14 days, etanercept = 7 days). 
Observed reﬁlls within seven days of the recommended dosing frequency were con-
sidered “on time”; intervals greater than seven days “longer”; and less than seven days 
“shorter”. Multivariable logistic regression analyses were performed to examine deter-
minants of longer reﬁll intervals. RESULTS: There were 26,103 prescription reﬁll 
events for adalimumab (N = 1,279 patients), and 48,859 for etanercept (N = 2,277 
patients). Rates of shorter reﬁll intervals were low: 3.7% for adalimumab and 3.5% 
for etanercept. Longer and on-time reﬁll interval rates were comparable for adalim-
umab (27.4% and 68.9%) and etanercept (29.5% and 67.0%), respectively. Regres-
sion analyses revealed etanercept longer intervals increased with duration of use (p < 
0.01), female gender (p < 0.01), and lack of insurance (p < 0.01), but decreased with 
older age (p < 0.01). A similar pattern emerged for adalimumab. CONCLUSIONS: 
More than one in four of all adalimumab and etanercept prescription reﬁll events in 
RA had longer reﬁll intervals than recommended. Further research is warranted assess-
ing the clinical and economic consequences of delays in prescription reﬁlls, which may 
be suggestive of under-dosing.
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ANTI-TUMOR NECROSIS FACTOR SWITCHING, DISCONTINUATION, 
AND PERSISTENCE IN MANAGED CARE PATIENTS WITH 
RHEUMATOID ARTHRITIS
Buysman E1, Tang B2, Carter C2, Piech CT2
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OBJECTIVES: To evaluate switching, discontinuation, and persistence among patients 
with RA receiving anti-TNFs. METHODS: This was a retrospective cohort study of 
RA patients, in a large managed care database, using their ﬁrst anti-TNF January 1, 
2005 -June 30, 2006. Patients were required to have ≥30 months of continuous plan 
eligibility: 6 months prior to and 24 months following their index anti-TNF date, and 
no evidence of pre-index biologic use. For patients with index adalimumab (ADA) or 
etanercept (ETA), a gap in days’ supply exceeding 60 days (i.e., no ﬁlls between 
prescription ﬁll dates and prescription ﬁll date + days supply + 60) indicated discon-
tinuation. For patients with index inﬂiximab (IFX), a gap in medical claims for infu-
sions >8 weeks + 60 days indicated discontinuation. Switching was deﬁned as use of 
a new biologic post-index. Persistence was deﬁned as continuous use of index anti-
TNF without discontinuation or switching. Differences in switching, discontinuation, 
and persistence rates were evaluated.RESULTS: A total of 1780 patients were ana-
lyzed: ADA = 601 (33.8%); ETA = 785 (44.1%); IFX = 394 (22.1%). Over three-
quarters (77%) were female; mean age was 50.1 years. IFX patients were older and 
had a higher Charlson-Quan comorbidity score than ADA or ETA patients. Each 
treatment group experienced switching (ADA = 13.1%, ETA = 11%, IFX = 13.5%). 
The IFX group had the lowest rate of discontinuation (37.6%) and greatest persistence 
(49%) compared to ADA (57.2% discontinuation, 29.6% persistence; p < 0.0001 for 
both) or ETA (57.5% discontinuation, 31.6% persistence; p < 0.0001 for both). 
CONCLUSIONS: These results indicate that among RA patients receiving anti-TNFs, 
the portion that switch does not vary by treatment in the 2 years following start of 
therapy. However, differences in discontinuation and persistence were noted. Studies 
are needed to investigate reasons for and impact of discontinuation and persistence 
on clinical and economic outcomes.
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PARTICIPATION, SATISFACTION AND KNOWLEDGE LEVEL AMONG 
PSORIATIC ARTHRITIS AND CUTANEOUS PSORIASIS PATIENTS
Tabolli S, di Pietro C, Renzi C
IDI IRCCS Rome, Rome, Italy
OBJECTIVES: To examine attitudes and satisfaction with decision-making among 
psoriatic arthritis (PA) patients, comparing them with cutaneous psoriasis (CP) 
patients. A further aim was to analyse factors associated with patients preferring an 
active participation and patient satisfaction. METHODS: A questionnaire was self-
completed after a routine medical visit by a consecutive sample of 231 psoriasis 
patients, including 33 PA patients. The questionnaire was based on previously pub-
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lished instruments and included neutrally worded questions in order to minimise 
acquiescence response bias. RESULTS: Among patients with CP and PA 27.3% and 
28.1%, respectively, preferred to leave decisions entirely to the doctor, while 72.7% 
and 71.9%, respectively, wanted to be involved in decision-making. Good knowledge 
level on psoriasis treatments was shown by 17.0% and 21.4% of CP and PA patients. 
Among PA patients, overall satisfaction was associated with doctors having asked 
patients if they had preferences or concerns, if they considered patients’ preferences 
and if they informed patients about treatment options and potential side-effects. At 
multivariable analysis information on treatment side-effects (OR = 5.11; 95%CI 
2.5–15.0; p < 0.001) and information on treatment options (OR = 3.15; 95%CI 
1.4–7.1; p = 0.006) were associated with overall satisfaction, controlling for diagnosis 
and other potential confounders. CONCLUSIONS: The majority of patients with PA 
and CP wanted to participate in decision-making, however we found substantial 
knowledge gaps. Satisfaction was associated with doctors providing information and 
actively involving patients in decision-making.
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CAPTURING DATA ON HEALTH CARE USE AND COSTS FOR PATIENTS 
WITH OSTEOARTHRITIS: AGREEMENT BETWEEN A PATIENT-
COMPLETED QUESTIONNAIRE AND ADMINISTRATIVE RECORDS
Pinto D, Robertson MC, Hansen P, Abbott JH
University of Otago, Dunedin, Otago, New Zealand
OBJECTIVES: Estimating health care costs is an essential step in the economic evalu-
ation of osteoarthritis-related treatments. We investigated the extent of agreement 
between a questionnaire and administrative records for capturing these costs for 
patients with osteoarthritis (OA). METHODS: Participants with hip and/or knee OA 
completed a questionnaire about their health care use over three months. We gathered 
equivalent data from four administrative databases. Using the kappa statistic (Κ) we 
assessed the extent of agreement between the methods for dichotomous (yes/no) 
reporting of health services. We used Bland-Altman comparisons of agreement to 
assess the reporting methods for systematic biases in the recording of visit quantity 
and costs. RESULTS: We recruited 50 participants, mean ± SD age 70.0 ± 7.9 years, 
58% female, with primary complaints of knee (62%) or hip OA. Agreement between 
the two methods was fair for specialist (Κ = 0.24 to 0.36) and general practitioner 
(GP) visits (Κ = 0.38), and moderate to substantial for the majority of medications 
reported (Κ = 0.41–0.71). Participants accurately reported number of visits and medi-
cations used but were not accurate when reporting out-of-pocket costs for GP services. 
Cost totals based on the questionnaire were in agreement with database-derived costs 
when considering societal costs. The cost of the questionnaire-based method was less 
than one-third of the cost of accessing the administrative databases. CONCLUSIONS: 
A patient-completed questionnaire is feasible, captures data on health care use that 
are in agreement with administrative databases, and can be used for capturing societal 
costs for patients with hip and/or knee OA.
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ASSESSING THE EQUIVALENCE OF ELECTRONIC AND PAPER DATA 
COLLECTION OF EQ-5D DATA IN RHEUMATOID ARTHRITIS
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OBJECTIVES: Electronic methods (ePRO, E) are increasingly being used for patient 
diaries and questionnaires. Where paper (P) instruments are migrated to E it is neces-
sary to compare to the original to to determine if the different modalities are equiva-
lent. We have carried out an equivalence study of a number of instruments including 
the EQ-5D in rheumatoid arthritis. METHODS: A total of 43 patients (31 female) 
aged 32–83 years took part in a single session during which they completed P and E 
(Palm TX handheld) assessments in randomised order, with a 45 minute interval 
between the two modes. Assessments included measures of pain, fatigue, disability 
and health status. RESULTS: Mean scores were similar between the two modes. Utility 
P: 0.612; E: 0.608; Effect size of P-E difference: −0.017. ICC = 0.79. VAS P: 64.2; E: 
64.5; Effect size: 0.013; ICC = 0.75. All patients found both P and E either very easy 
or quite easy to use. CONCLUSIONS: The low magnitude of the effect sizes does not 
suggest that any signiﬁcant differences are occurring between modes. ICC values met 
the a priori threshold of 0.75 for “excellent” agreement, and were in general agree-
ment with paper retest reliability for this scale.This study supports the equivalence of 
an electronic method of completing the EQ-5D instrument compared to the original 
paper version.
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INJECTION SITE REACTION QUESTIONNAIRE: AN ADEQUATE TOOL 
FOR MEASURING INJECTION SITE REACTIONS?
Lee EH1, Jutkowitz E1, Parasuraman S2, Derk C1, Pizzi LT1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Johnson & Johnson, New Brunswick, 
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OBJECTIVES: Evaluate the Injection Site Reaction Questionnaire (ISRQ) to measure 
injection site reactions (ISR) from anti-TNF therapy for Rheumatoid Arthritis (RA). 
METHODS: Patients ≥18 years who received subcutaneous etanercept or adalimumab 
from 2007–2009 were identiﬁed by their rheumatologist and invited to complete the 
ISRQ at an academic practice. The ISRQ included an ISR symptom battery (redness, 
bruising, hot to touch, pain, swelling, itching, stinging and/or burning) and health care 
utilization battery (call/visit the doctor, ER, medication use, over the counter treat-
ments). The ISRQ also captured patient demographics, missed work due to ISR, and 
changes in therapy due to ISR (postponements, schedule changes, discontinuations). 
A post hoc analysis was conducted to explore ISR severity using items in the severity 
battery: mild (1–2 symptoms), moderate (3 symptoms), and severe (≥4 symptoms). 
Each severity group was then assessed for differences in ISR health care utilization 
(physician services and medication use). RESULTS: Forty-one patients were recruited. 
All ISR characteristics in the ISRQ and 50% of items for ISR management elicited 
a response. There were no responses for missed work due to ISR and 66% of 
change in therapy items received a response. In the post hoc analysis, one patient in 
the mild group used physician services compared to 1 (14%) in the moderate group 
and 0 in the severe group. CONCLUSIONS: The ISRQ is the ﬁrst tool available for 
capturing patient-reported characteristics and outcomes of ISR. Initial experiences 
suggest that item completion rates are favorable, and the symptom battery can 
be applied to estimate ISR severity. Low responses to certain utilization and productiv-
ity items suggest that these items may extend the tool’s response burden, or be of 
low perceived relevance. Given the signiﬁcant cost of anti-TNF therapy, the ISRQ can 
be useful in analyses aimed at weighing the costs and outcomes of this medication 
class.
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TREATMENTS AMONG THE MEDICARE POPULATION
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OBJECTIVES: To determine preferences and marginal willingness to pay (MWTP) 
for osteoarthritis (OA) treatments, including complementary and alternative medicine 
(CAM) among a sample of Medicare beneﬁciaries 65+. METHODS: A discrete choice 
conjoint analysis was conducted with 181 participants recruited from 4 senior centers 
and one internal medicine practice in Memphis, TN. Data were collected via computer 
survey, and analyzed using Sawtooth Software according to covariates of age, race, 
gender, income, education, disability status, and OA duration. Utility data and MWTP 
were derived from multinomial logit analysis. This study was conducted in accordance 
with ISPOR’s Checklist for Good Research Practices in Conjoint Analysis. RESULTS: 
Prescription pain (.35) and over-the-counter medications (.34) had the highest utility 
and physical therapy (−.72) had the lowest utility among conventional treatments. The 
most preferred CAM therapy was prayer/spiritual healing with a utility value of .71. 
The highest utility value for combination therapy was prescription pain medication 
and acupuncture (.42). The price attribute followed the expected trend as lower prices 
were associated with higher utility. This sample was willing to pay ﬁve dollars more 
for prayer/spiritual healing and was willing to pay nine dollars less for a combination 
of physical therapy and chiropractic than the referent (a combination of prescription 
OA medication and herbal/mineral supplements). CONCLUSIONS: This sample has 
signiﬁcant preference for CAM in addition to conventional treatments. These data 
suggest that health care providers should involve patients in treatment decisions to 
optimize treatment acceptance and compliance. Although the data show that prayer/
spiritual healing is a valued therapy, it is not the only treatment preferred. This result 
may reﬂect a desire for a more holistic view of health care. As options for CAM alone 
and in conjunction with conventional medications become increasingly available, the 
relationship between preferences illustrated by this study and health outcomes is 
important to examine.
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ACUPUNCTURE OR PHYSICAL THERAPY? LOW-BACK PAIN PATIENTS’ 
CHOICE—A QUALITATIVE STUDY IN A GENERAL HOSPITAL, CHINA
Zhang Y, Cheng LJ
University of Macau, Taipa, Macau
OBJECTIVES: Both physical and acupuncture therapy are clinical choices available 
for low-back pain (LBP) patients. The study investigates under which condition LBP 
patients would choose either therapy, or both. METHODS: LBP patients, aged 18 
years old and above, received semi-structured, face-to-face interviews in the rehabilita-
tion department of a general hospital, in Guangdong Province, China. The patients 
were asked questions about their disease history, their perception of physical and 
acupuncture therapy, in terms of efﬁcacy and risks, previous experience of receiving 
two therapies, medical expense, distance to medical facilities, others’ experience and 
ﬁnally, under which condition they would change to acupuncture. In addition, the 
patients were also encouraged to talk about other factors affecting their preference. 
RESULTS: 13 LBP patients participated in this study. Patients’ perception of efﬁcacy 
and risk of therapies, previous experience, others’ recommendation (medical staff and 
friends), and hospital size are all considered as determinants of LBP patients’ clinical 
choice in the interview. Among them, medical staff played a key role, particularly 
when patients had limited knowledge of the efﬁcacy of acupuncture therapy. Previous 
negative experience of the patients or family members also led them to choose physical 
therapy instead. Although medical expense and distance are regarded as important 
determinants in patients’ choice in literature, in this study it is interesting to say they 
are not as important as literature suggests. Some patients indicated that they would 
like to receive acupuncture therapy, if they suffer low back pain longer and current 
therapeutic effect is not satisfactory. CONCLUSIONS: Our results suggest that most 
LBP patients who visit physical doctors do not have clear understanding of acupunc-
ture therapy. On the other hand, the more recommendations from medical staff or 
friends, the more possible that LBP patients would prefer acupuncture therapy.
